Jazz Pharmaceuticals agreed to acquire portfolio company Actio Biosciences for $820M.
AUG 10, 2026
Biotechnology company developing precision therapeutics for genetically defined rare and common diseases
Biotechnology company developing precision therapeutics for genetically defined rare and common diseases. It combines genetics, drug discovery, and data science to identify shared disease biology and develop targeted medicines. Its lead program, ABS-1230, is a potential first-in-class small-molecule KCNT1 inhibitor for KCNT1-related epilepsy. Actio was acquired by Jazz Pharmaceuticals.